{"id":"NCT02155660","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","officialTitle":"A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06-25","primaryCompletion":"2018-04-09","completion":"2018-04-09","firstPosted":"2014-06-04","resultsPosted":"2019-06-26","lastUpdate":"2019-06-26"},"enrollment":2255,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Very Severe Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Benralizumab Arm A","otherNames":[]},{"type":"DRUG","name":"Benralizumab Arm B","otherNames":[]},{"type":"DRUG","name":"Benralizumab Arm C","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Benralizumab Arm A","type":"EXPERIMENTAL"},{"label":"Benralizumab Arm B","type":"EXPERIMENTAL"},{"label":"Benralizumab Arm C","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.","primaryOutcome":{"measure":"Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL","timeFrame":"Immediately following the first IP dose through week 56","effectByArm":[{"arm":"Benralizumab 10 mg","deltaMin":0.99,"sd":null},{"arm":"Benralizumab 30 mg","deltaMin":1.21,"sd":null},{"arm":"Benralizumab 100 mg","deltaMin":1.09,"sd":null},{"arm":"Placebo","deltaMin":1.17,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"0.0638"},{"comp":"OG001 vs OG003","p":"0.6575"},{"comp":"OG002 vs OG003","p":"0.3988"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":17},"locations":{"siteCount":356,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Chile","Colombia","Croatia","Denmark","France","Israel","Mexico","New Zealand","Norway","Peru","Philippines","Poland","Serbia","Slovenia","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","Vietnam"]},"refs":{"pmids":["31575508","31112385"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2563&filename=D3251C00004%20-%20%20%20Statistical%20Analysis%20Plan_Redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2563&filename=Terranova%20CSP%20and%20last%20amendment_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":144,"n":561},"commonTop":["Upper respiratory tract infection","Bronchitis","Viral upper respiratory tract infection","Urinary tract infection","Headache"]}}